Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 581 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06605664RecruitingPhase 2
New MRI scan for liver cancer with radiation and immunotherapy
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Taoyuan City, TaiwanAges 18 years+ - NCT06218420RecruitingPhase 2
Radiation to bridge to liver transplant
This study tests whether a precise type of radiation (called stereotactic body radiotherapy or SBRT) can be used as a 'bridge' to keep your liver cancer from growing while you wait for a liver transplant. It may help more people stay healthy enough to receive a transplant.
ParisAges 18 years+ - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT05866783Recruiting
Blood test to predict cancer coming back after liver transplant
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
GhentAges 18 years+ - NCT07850882Recruiting
Virus injection plus immunotherapy for advanced colorectal, stomach, or liver cancer
This study tests whether a special virus injected directly into tumors can help your body fight cancer when combined with an immunotherapy drug. It is for people with advanced colorectal, stomach, or liver cancer that has spread and who have tumors that can be reached for injection.
Guangdong, FoshanAges 18–75 - NCT06498622RecruitingPhase 2
Liver cancer relapse prevention after surgery
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Fuyang, AnhuiAges 18–80 - NCT07776080RecruitingPhase 2
Immunotherapy, targeted therapy, and radiation for liver cancer with portal vein clot
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
Wuhan, HubeiAges 18–75 - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT07337421RecruitingPhase 2
Chemo infusion after liver cancer surgery to lower recurrence risk
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Yangzhou, JiangsuAges 18–75 - NCT06382103Recruiting
Liver cancer study after surgery or pre-surgery therapy
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
ShanghaiAges Any age - NCT07178587Recruiting
New PET scan for liver and neuroendocrine tumors
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
BrestAges 18 years+ - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06280105RecruitingPhase 2
Testing cadonilimab and regorafenib for liver cancer after other treatments fail
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Fuzhou, FujianAges 18–75 - NCT06954116RecruitingPhase 2
Iparomlimab and Tuvonralimab before surgery for liver cancer
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
Wuhan, HubeiAges 18–75 - NCT06624189Enrolling by invitation
Liver cancer screening decision support for cirrhosis patients
This trial tests a tool to help doctors and patients decide when to screen for liver cancer. It is for people with cirrhosis who have not had imaging in the last 6 months.
New York, New YorkAges 18 years+ - NCT06374485RecruitingPhase 1
AU409 capsule for advanced liver cancer after other treatments fail
This trial tests a new capsule called AU409 for people with advanced liver cancer (HCC) who have already tried standard treatments and they no longer work. The goal is to see if AU409 can help control the cancer.
Hong KongAges 18–75 - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06166576RecruitingPhase 2
Radioembolization for Liver Cancer with Vein Involvement
This trial tests a targeted radiation treatment (radioembolization) for liver cancer that has grown into the main vein (portal vein) but is still limited to one lobe of the liver. It is for people who have not received any prior cancer treatment and whose liver function is still fairly good.
Ilsan, Gyeonggi-doAges 18 years+ - NCT06849180Recruiting
Personalized Treatment for Advanced Combined Liver Cancer
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
Nanjing, JiangsuAges 18 years+ - NCT04595864RecruitingPhase 3
Chemotherapy into the liver before transplant for liver cancer
This trial tests whether giving chemotherapy directly into the liver blood supply before a liver transplant can help people with liver cancer that is beyond standard transplant criteria. It may help lower cancer risk around the time of transplant while keeping people healthy enough to receive the transplant.
Nanjing, JiangsuAges 18–75 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT07341321Recruiting
Covid-19 vaccine in liver cancer patients on immunotherapy
This study looks at how the COVID-19 mRNA vaccine works in people with liver cancer who are being treated with immunotherapy. It may help show if the vaccine is safe and effective for this group of patients.
GrazAges Any age
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 581 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.